Michael R. Robinson
AbbVie (United States) · 128 works · 14,118 citations · h-index 40
Top works
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report
- Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
- Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma
- Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant
- A randomized, placebo‐controlled, double‐masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis
- Lens Capsule Abnormalities in Alport's Syndrome
- Pharmacokinetics of a Sustained-Release Dexamethasone Intravitreal Implant in Vitrectomized and Nonvitrectomized Eyes
- Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy
- Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease
- Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Applications
- The pharmacokinetics of rituximab following an intravitreal injection
- Vitreous VEGF Clearance Is Increased after Vitrectomy
- Iris Involvement in Primary Intraocular Lymphoma
- A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide
- A Novel Bioerodible Deep Scleral Lamellar Cyclosporine Implant for Uveitis
- Transport Barriers in Transscleral Drug Delivery for Retinal Diseases
- Controlled Drug Release from an Ocular Implant: An Evaluation Using Dynamic Three-Dimensional Magnetic Resonance Imaging
- 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients